Beacon Equity Research Clients

Cannabis Science, Inc. (CBIS)

Cannabis Science, Inc. (CBIS) is a leader in cannabinoid research and development for unmet medical needs. The company is presently working with CBR International to develop a Pre-IND application focusing on CS-S/BCC-1 topical cannabis-based preparations for treating basal and squamous carcinomas. Cannabis Science additionally works with leading experts in HIV drug development, medicinal characterization, and clinical research for the development, production, and commercialization of Phytocannabinoid-based pharmaceutical products.

Although cannabis has been utilized for medicinal purposes for thousands of years, very little has been known about how it actually worked until very recently. Modern advances in science have opened the door for the development, production, and commercialization of a variety of effective, whole-plant cannabinoid-based pharmaceutical products with a broad spectrum of important applications. Some well-known cannabis uses include nausea alleviation, appetite stimulation for people with HIV/AIDS and cancer, treating chronic pain and reducing muscle spasms associated with neuromuscular disorders like MS, and spinal cord injuries. Some more current uses of cannabis are, at this stage, poorly understood, like its effectiveness in alleviating certain autoimmune disorders such as Crohn’s Disease.

The aim of Cannabis Science is to develop more effective ways of producing and commercializing whole-plant cannabinoid-based pharmaceutical products. New uses for cannabis are still being discovered, including the recent discovery that topical cannabis preparations can be effectively used against the deadly, antibiotic-resistant flesh-eating disease MRSI. Other topical applications – largely non-psychoactive – would target localized pain, like arthritis and burns, as well as neuropathic pain, for which there are currently few effective treatments.

Beacon Equity Research Blog

Cannabis Science, Inc. Message Board